Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.2K
Overview
45.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

644
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
644
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

3.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
3.4K
Cancer Vaccines01:30

Cancer Vaccines

496
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
496
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.2K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.2K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

890
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
890

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Degradation of the pyrethroid insecticide dimefluthrin in a water-sediment system: detailed insight into the non-extractable residues.

Journal of pesticide science·2026
Same author

Publisher Correction: Multi-ancestry genome-wide association analyses of refractive error augment genetic discovery and polygenic prediction.

Nature genetics·2026
Same author

Genome-Wide Meta-Analysis for High Myopia Provides Insights into Disease Mechanisms and Reveals a Causal Link to Primary Open-Angle Glaucoma.

Ophthalmology science·2026
Same author

Multi-ancestry genome-wide association analyses of refractive error augment genetic discovery and polygenic prediction.

Nature genetics·2026
Same author

Clinical performance of the multiplex solid-phase "Direct Strip PCR" for infectious uveitis: a multicenter diagnostic accuracy study.

Japanese journal of ophthalmology·2026
Same author

High-Contrast Projection Mapping under Light Field Illumination with LED Display and Aperiodic Lens Array.

IEEE transactions on visualization and computer graphics·2026

Related Experiment Video

Updated: Aug 30, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K

Current Vaccine Platforms in Enhancing T-Cell Response.

Takehiro Ura1, Masaki Takeuchi1, Tatsukata Kawagoe1,2

  • 1Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.

Vaccines
|August 26, 2022
PubMed
Summary

This review explores T cell-mediated immunity in vaccine development, highlighting viral vectors and mRNA technologies. Understanding these platforms is key to creating effective vaccines against infectious diseases.

Keywords:
T-cell-mediated immunityinfectious diseasesmRNA vaccinesvaccinesviral vectors

More Related Videos

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

8.7K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.3K

Related Experiment Videos

Last Updated: Aug 30, 2025

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

8.8K
Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

8.7K
Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.3K

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • T cell-mediated immunity is crucial for effective vaccine development, influencing vaccine duration and cross-reactivity.
  • Pre-existing T cell immunity can reduce the severity of infectious diseases.
  • Various platforms aim to induce T cell-mediated immunity, enhancing vaccine immunogenicity through controlled delivery.

Purpose of the Study:

  • To review T cell responses induced by different vaccine technologies and delivery platforms against infectious diseases.
  • To discuss the advantages and challenges of viral vectors and mRNA vaccines for T cell induction.
  • To explore future directions in vaccine development focusing on T cell-mediated immunity.

Main Methods:

  • This review synthesizes information on vaccine technologies and delivery platforms.
  • It analyzes T cell responses elicited by various vaccine approaches.
  • The discussion includes viral vectors and mRNA vaccine technologies.

Main Results:

  • Viral vectors can induce robust T cell immunity but require careful selection due to anti-vector immunity.
  • mRNA vaccines offer rapid manufacturing and improved stability/efficacy through modification and encapsulation.
  • Both platforms are critical for inducing T cell-mediated immunity.

Conclusions:

  • Optimizing vaccine immunogenicity involves controlling kinetics and targeted delivery.
  • Selecting appropriate viral vectors and enhancing mRNA vaccines are key strategies.
  • Future vaccine development should focus on advanced platforms to elicit strong T cell responses for infectious diseases.